Global Cancer Diagnostics Partnering Deal Terms and and Agreement Analysis Report 2023: Access to Over 900 - Access to Company A-Z, Headline, Upfront, Milestone, Upfront and Royalty Data

News provided by

Jun 22, 2023, 05:30 ET

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023" report has been added to ResearchAndMarkets.com's offering.

The Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 report provides an understanding and access to over 900 cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest cancer diagnostics agreements announced in the life sciences since 2016.

The report takes the reader through a comprehensive review cancer diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering cancer diagnostics partnering deals.

The report presents financial deal term values for cancer diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the cancer diagnostics partnering field; both the leading deal values and most active cancer diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 900 online deal records of actual cancer diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of cancer diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer diagnostics dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer diagnostics deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostics dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostics deals announced by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by cancer diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:

In-depth understanding of cancer diagnostics deal trends since 2016
Access to headline, upfront, milestone and royalty data
Detailed access to actual cancer diagnostics contracts entered into by leading biopharma companies
Identify most active cancer diagnostics dealmakers since 2016
Insight into terms included in a cancer diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Partial list of companies featured

Aetna
Amgen
Angle
Axela
Bayer
BL&H
Ceres
COTA
CSIRO
Cypre
D-Eye
Dako
Dell
Eigen
Falco
Fscan
GIMDx
Glide
Grail
IBM
iCAD
IPMD
Item
KEW
Lab21
Mavig
Medx
MIODx
NASA
Ochin
Orot+
RAW
Roche
Sebia
Seer
TaiRx
Take2
Telik
UPMC
ZoBio

For more information about this report visit https://www.researchandmarkets.com/r/dy2tsi

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets